Findings

What do systematic reviews say?

15 questions · 15 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 8 · 53.3%Moderate 7 · 46.7%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Gabapentin vs placebo · Reduction in seizure frequency of ≥ 50%: primary analysisNumber of seizures reported in seizure diary
  Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.89 [1.4, 2.55]
  6 studies · 1206 participants
  Moderate
Direct match · question page
- Oral gabapentin vs placebo · Change in muscle strength assessed as: % change in total muscle strength from baseline
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Low
Direct match · question page
- Oral gabapentin vs placebo · Acquiring ability to walk
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 73 participants
  Low
Direct match · question page
- Gabapentin vs placebo · Adverse effects: somnolenceNumber of participants experiencing somnolence
  Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.93
  6 studies · 1206 participants
  Moderate
Direct match · question page
- Oral gabapentin vs placebo · Change in quality of life
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 67 participants
  Low

Gabapentin vs placebo

Treatment withdrawalNumber of participants withdrawn for any reason · people with drug‐resistant focal epilepsy

Gabapentin showed no clear difference in treatment withdrawalNumber of participants withdrawn for any reason compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.05 [0.74, 1.49]
6 studies · 1206 participants
Moderate

Oral gabapentin vs placebo

Time from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Moderate

Oral gabapentin vs placebo

Adverse events related to treatment · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Gabapentin vs placebo

50% or greater reduction in seizure frequency Number of seizures · people with drug‐resistant focal epilepsy

Gabapentin probably leads to higher reduction in seizure frequency of ≥ 50%: primary analysisNumber of… compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.89 [1.4, 2.55]
6 studies · 1206 participants
Moderate

Gabapentin vs placebo

Adverse effects: ataxia Number of participants experiencing ataxia · people with drug‐resistant focal epilepsy

Gabapentin may leads to higher adverse effects: ataxiaNumber of participants experiencing ataxia compared with placebo (low certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.01
3 studies · 787 participants
Low

Gabapentin vs placebo

Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy

Gabapentin probably leads to higher adverse effects: dizzinessNumber of participants experiencing… compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 2.43
6 studies · 1206 participants
Moderate

Gabapentin vs placebo

Adverse effect: fatigue · people with drug‐resistant focal epilepsy

Gabapentin may leads to higher adverse effects: fatigueNumber of participants experiencing fatigue compared with placebo (low certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.95
5 studies · 1161 participants
Low

Gabapentin vs placebo

Nausea · people with drug‐resistant focal epilepsy

Gabapentin probably leads to lower adverse effects: nauseaNumber of participants experiencing nausea compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 0.95
4 studies · 1034 participants
Moderate

Gabapentin vs placebo

Somnolence · people with drug‐resistant focal epilepsy

Gabapentin probably leads to higher adverse effects: somnolenceNumber of participants experiencing… compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 1.93
6 studies · 1206 participants
Moderate

Gabapentin vs placebo

Adverse effects: headache · people with drug‐resistant focal epilepsy

Gabapentin probably leads to lower adverse effects: headacheNumber of participants experiencing headache compared with placebo (moderate certainty).

1 finding from 1 review

Gabapentin add‐on treatment for drug‐resistant focal epilepsy 2021 · Cochrane Headline outcomes only
RR 0.79
6 studies · 1206 participants
Moderate

Oral gabapentin vs placebo

Acquiring ability to walk · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral gabapentin vs placebo

Change in pulmonary function · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Oral gabapentin vs placebo

Change in disability score · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Oral gabapentin vs placebo

Muscle strength · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low